September 5, 2025

Vistry Group Plc appoints Sue Farr as Independent Non-Executive Director

Vistry Group has appointed Sue Farr as an Independent Non-Executive Director from 1 October 2025. She will join the Nomination, Audit and Remuneration Committees, bringing extensive marketing and corporate communications expertise to the Board...

Ashmore Group Plc reports resilient FY25 results with strong investment performance

Ashmore Group posted FY25 assets under management of US$47.6bn, supported by US$4.1bn positive investment performance and improved net outflows of US$5.8bn. Profit before tax was £108.6m, with a final dividend of 12.1p maintained, taking the full-year payout to 16.9p...

HUTCHMED to present new lung cancer and oncology data at WCLC and CSCO 2025

HUTCHMED announced that updated data on savolitinib in NSCLC and other pipeline compounds will be presented at the World Conference on Lung Cancer in Barcelona and the CSCO Annual Meeting in China this September. Presentations include studies on savolitinib, surufatinib, fruquintinib and first-in-human results for HMPL-653...

Surface Transforms appoints Paul Marr as Non-Executive Director

Surface Transforms has appointed Paul Marr to its Board as Non-Executive Director. Marr brings over 40 years of global automotive manufacturing and operational leadership experience, including senior roles at General Motors and other international groups...
Search

Funds

September 5, 2025

Vistry Group Plc appoints Sue Farr as Independent Non-Executive Director

Vistry Group has appointed Sue Farr as an Independent Non-Executive Director from 1 October 2025. She will join the Nomination, Audit and Remuneration Committees, bringing extensive marketing and corporate communications expertise to the Board...

Ashmore Group Plc reports resilient FY25 results with strong investment performance

Ashmore Group posted FY25 assets under management of US$47.6bn, supported by US$4.1bn positive investment performance and improved net outflows of US$5.8bn. Profit before tax was £108.6m, with a final dividend of 12.1p maintained, taking the full-year payout to 16.9p...

HUTCHMED to present new lung cancer and oncology data at WCLC and CSCO 2025

HUTCHMED announced that updated data on savolitinib in NSCLC and other pipeline compounds will be presented at the World Conference on Lung Cancer in Barcelona and the CSCO Annual Meeting in China this September. Presentations include studies on savolitinib, surufatinib, fruquintinib and first-in-human results for HMPL-653...

Surface Transforms appoints Paul Marr as Non-Executive Director

Surface Transforms has appointed Paul Marr to its Board as Non-Executive Director. Marr brings over 40 years of global automotive manufacturing and operational leadership experience, including senior roles at General Motors and other international groups...
Search

Funds

September 5, 2025

FTSE 100

Funds